Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
<< anterior 21 a 40 de 71 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas Cita con resumen
Byrne RA, Kastrati A. Drug-eluting stent trials: too much non-inferiority, too little progress?. Lancet 2014;383:386-8. [Ref.ID 97078]
22. Cita con resumen
Anónimo. Évérolimus et sclérose tubéreuse de Bourneville. Prescrire 2013;33:731. [Ref.ID 96231]
23. Cita con resumen
Anónimo. Évérolimus après transplantation hépatique. Prescrire 2013;33:730. [Ref.ID 96230]
24.Tiene citas relacionadas
Bissler JJ, Kingswood JC, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeler D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381:817-24. [Ref.ID 95086]
25.Tiene citas relacionadas
Sooriakumaran P, Anderson CJ. Everolimus for renal angiomyolipoma in tuberous sclerosis. Lancet 2013;381:783-5. [Ref.ID 95081]
26. Cita con resumen
Bailey DG, Dresser G, Arnold MO. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? . Can Med Assoc J 2013;185:309-16. [Ref.ID 94799]
27. Cita con resumen
Stefanini GG, Homes Jr DR. Drug therapy: drug-eluting coronary-artery stents. N Engl J Med 2013;368:254-65. [Ref.ID 94789]
28. Cita con resumen
Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381:125-32. [Ref.ID 94767]
29. Cita con resumen
Geoerger B, Blockus H. Everolimus for astrocytomas in tuberous sclerosis complex. Lancet 2013;381:95-6. [Ref.ID 94765]
30.Tiene citas relacionadas Cita con resumen
Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabaté M, Kim H-S, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-402. [Ref.ID 92725]
31.Tiene citas relacionadas
Ormiston JA, Webster MW. Stent thrombosis: has the firestorm been extinguished?. Lancet 2012;379:1368-9. [Ref.ID 92723]
33. Cita con resumen
Baselga J, Campone M, Piccart M, Burris III HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lewohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9. [Ref.ID 92340]
34.
Goirand F, Royer B, Hulin A, Saint-Marcoux F, pour le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. Niveau de preuve du suivi thérapeutique pharmacologique de l'évérolimus. Therapie 2011;66:57-61. [Ref.ID 90468]
35.Tiene citas relacionadas Cita con resumen
Silber S, Windecker S, Vranckx P, Serruys PW, on behalf of the RESOLUTE All Comers investigators. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011;377:1241-7. [Ref.ID 90368]
36.Tiene citas relacionadas
Lassen JF. Long-term safety and efficacy of drug-eluting stents. Lancet 2011;377:1213-4. [Ref.ID 90365]
37.Tiene citas relacionadas
Franz DN, Kreuger DA. Everolimus and giant-cell astrocytomas in tuberous sclerosis. The authors reply. N Engl J Med 2011;364:577. [Ref.ID 90182]
38.Tiene citas relacionadas
Jia J, Xiong L, Chen S. Everolimus and giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2011;364:577. [Ref.ID 90181]
39.Tiene citas relacionadas
Nawashiro H, Shinomiya N. Everolimus and giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2011;364:576-7. [Ref.ID 90180]
40.
Yao YC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EGE, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K, for the RAD001 in Advanced Neuroendocrine Tumors Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23. [Ref.ID 90170]
Seleccionar todas
 
<< anterior 21 a 40 de 71 siguiente >>